Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04357457

Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia — AIRVM-COVID  

Covid 19 Clinical Trial

Official title:
Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia: a Randomized Controlled Double-blind Study From the Skip-icu Consortium

Clinical Trial Summary

The COVID-19 outbreak is associated with a surge in ICU bed requirement and substantial mortality (estimated between 0.5% and 1%). Admission in the intensive care unit (ICU) and need for mechanical ventilation is reportedly associated with an estimated hospital mortality of more than 30%. Furthermore, the surge in ICU bed requirement is a worldwide-shared issue, leading to sub-optimal ICU management. In acute respiratory failure due to COVID-19-related pneumonia, vasoplegia with vascular enlargement inside the lung lesions and dilation of small vessels seen on chest CT scan largely account for severe hypoxemia whose physiological response is hyperventilation leading to hypocapnia. Almitrine, initially described to reduce intrapulmonary shunt by enhancement of hypoxic pulmonary vasoconstriction in combination with inhaled nitric oxide (iNO), redistributes pulmonary blood flow from shunt areas to lung units with normal ventilation/perfusion (VA/Q) ratio. Low dose of intravenous almitrine (2 µg.kg-1.min-1) alone also improves oxygenation (without combination with iNO) by selective pulmonary vasoconstriction of precapillary pulmonary arteries perfusing lung areas exposed to a hypoxic challenge with a slight increase in mean arterial pulmonary. Therefore, our hypothesis is that 5 days of low dose of almitrine therapy may improve the ventilation-perfusion (VA/Q) ratio at a relatively early stage of this specific lung disease and limit respiratory worsening and subsequent need for mechanical ventilation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04357457
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Completed
Phase Phase 3
Start date September 3, 2020
Completion date December 17, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT04333732 - CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION Phase 3
Terminated NCT04435795 - Inhaled Ciclesonide for Outpatients With COVID19 Phase 2/Phase 3
Completed NCT04357444 - Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19 Phase 2
Completed NCT04357834 - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Not yet recruiting NCT05052320 - Audiological Assessment of Recovered Covid 19 Subjects.
Withdrawn NCT04426344 - Core Warming of COVID-19 Patients N/A
Recruiting NCT05595031 - Evaluation of the Clinical Impact of Corticosteroid Duration on SARS-CoV-2 (COVID-19 WHO)
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3
Terminated NCT04401410 - Anti-SARS Cov-2 T Cell Infusions for COVID 19 Phase 1
Completed NCT04445337 - Stellate Ganglion Blockade in COVID-19 Positive Patients N/A
Active, not recruiting NCT04374487 - Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications Phase 2
Completed NCT04403243 - COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19 Phase 2
Completed NCT04375644 - Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT)
Completed NCT04394078 - Impact of COVID-19 Pandemic on Depression and Quality of Life
Recruiting NCT04407923 - Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment
Completed NCT04426305 - Community Health Workers Against COVID19 N/A
Withdrawn NCT04519411 - Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure N/A
Recruiting NCT04492514 - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation Phase 2
Completed NCT04399980 - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Phase 2
Completed NCT04403828 - Impact of COVID-19 on Personal Protection Among Dentist in Egypt